Roche has signed up for access to Vividion Therapeutics' proteomics screening platform and proprietary small molecule library to target E3 ligases and a range of oncology and immunology therapeutic targets.
Sandoz, a Novartis division, announced that the European Medicines Agency (EMA) has accepted for regulatory review their marketing authorisation applications for biosimilars to AbbVie‘s Humira (adalimumab) and Janssen‘s Remicade (infliximab)...